ProVise Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

ProVise Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,000	Closed	-$98K	–	318
2022 Q2	$98K	Sell	14,000 -5,000	-26%	-$36.7K	0.01%	321
2022 Q1	$158K	Hold	19,000	–	–	0.01%	363
2021 Q4	$129K	Hold	19,000	–	–	0.01%	386
2021 Q3	$101K	Hold	19,000	–	–	0.01%	371
2021 Q2	$109K	Hold	19,000	–	–	0.01%	383
2021 Q1	$88K	Hold	19,000	–	–	0.01%	349
2020 Q4	$63K	Hold	19,000	–	–	0.01%	339
2020 Q3	$56K	Hold	19,000	–	–	0.01%	288
2020 Q2	$88K	Hold	19,000	–	–	0.01%	273
2020 Q1	$73K	Hold	19,000	–	–	0.01%	260
2019 Q4	$71K	Hold	19,000	–	–	0.01%	305
2019 Q3	$101K	Hold	19,000	–	–	0.01%	303
2019 Q2	$73K	Hold	19,000	–	–	0.01%	310
2019 Q1	$97K	Hold	19,000	–	–	0.01%	301
2018 Q4	$36K	Hold	19,000	–	–	0.01%	300
2018 Q3	$72K	Hold	19,000	–	–	0.01%	322
2018 Q2	$59	Hold	19,000	–	–	﹤0.01%	320
2018 Q1	$45K	Hold	19,000	–	–	0.01%	300
2017 Q4	$74K	Hold	19,000	–	–	0.01%	315
2017 Q3	$48K	Hold	19,000	–	–	0.01%	314
2017 Q2	$52K	Hold	19,000	–	–	0.01%	323
2017 Q1	$37K	Hold	19,000	–	–	0.01%	319
2016 Q4	$20K	Hold	19,000	–	–	﹤0.01%	321
2016 Q3	$21K	Hold	19,000	–	–	﹤0.01%	320
2016 Q2	$13K	Buy	+19,000	New	+$15.3K	﹤0.01%	301

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProVise Management Group's CPRX Position: Q3 2022 in Review

ProVise Management Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2022, closing a stake of 14,000 shares — an estimated $98K sold.

ProVise Management Group first reported a position in CPRX in Q2 2016 and held it in 25 quarters. The position peaked at $158K in Q1 2022. 229 funds tracked by Wall St. Rank hold CPRX as of Q3 2022.

ProVise Management Group reported no remaining Catalyst Pharmaceutical position as of Q3 2022 after selling out during the quarter.
ProVise Management Group sold 14,000 Catalyst Pharmaceutical shares in Q3 2022, an estimated $98K.
ProVise Management Group first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 25 quarters.
ProVise Management Group's Catalyst Pharmaceutical position peaked at $158K in Q1 2022.
229 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2022.

Based on ProVise Management Group's 13F filing for Q3 2022, filed 9 Nov 2022.